https://orcid.org/0000-0002-1834-8035
References
- Centers for Disease Control and Prevention. Understanding the epidemic [cited 2022 Sep 25]. Available from: https://urldefense.com/v3/__https://www.cdc.gov/drugoverdose/epidemic/index.html__;!!LQC6Cpwp!oEYf2KxwqCKi6-xKn9gDEXtVEXZpRFTYbB8hbxXTj4wmTdV89V-wz_NW8pxeYSFViBDKHb9kmMR9hrFpag8-o_zIYm93f0ogvQ$
- Mattson CL, Tanz LJ, Quinn K, et al. Trends and geographic patterns in drug and synthetic opioid overdose deaths – United States, 2013–2019. MMWR Morb Mortal Wkly Rep. 2021;70(6):202–207.
- Sun EC, Dixit A, Humphreys K, et al. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ. 2017;356:j760.
- Park TW, Saitz R, Ganoczy D, et al. Benzodiazepine prescribing patterns and deaths from drug overdose among us veterans receiving opioid analgesics: case-cohort study. BMJ. 2015;350:h2698.
- Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012;125(1–2):8–18.
- Dasgupta N, Funk MJ, Proescholdbell S, et al. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Med. 2016;17(1):85–98.
- US Food and Drug Administration. FDA drug safety communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. FDA Drug Safety Communication; 2017 [cited 2022 Sep 25]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-serious-risks-and-death-when-combining-opioid-pain-or
- Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain–United States, 2016. JAMA. 2016;315(15):1624–1645.
- Jeffery MM, Hooten WM, Jena AB, et al. Rates of physician coprescribing of opioids and benzodiazepines after the release of the centers for disease control and prevention guidelines in 2016. JAMA Netw Open. 2019;2(8):e198325.
- Bohnert ASB, Guy GP Jr., Losby JL. Opioid prescribing in the United States before and after the centers for disease control and prevention’s 2016 opioid guideline. Ann Intern Med. 2018;169(6):367–375.
- National Poison Data System (NPDS). NPDS coding users’ manual version 4.0. American Association of Poison Control Centers; 2019.
- National Institute on Drug Abuse. Prescription opioids [cited 2022 Aug 31]. Available from: https://www.drugabuse.gov/publications/drugfacts/prescription-opioids
- US Department of Justice. Benzodiazepines. Drug & Chemical Evaluation Section; 2019 [cited 2022 May 1]. Available from: https://www.deadiversion.usdoj.gov/drug_chem_info/benzo.pdf
- Gummin DD, Mowry JB, Beuhler MC, et al. 2020 Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 38th annual report. Clin Toxicol. 2021;59(12):1282–1501.
- Linden A. Conducting interrupted time-series analysis for single- and multiple-group comparisons. Stata J. 2015;15(2):480–500.
- Townsend T, Cerdá M, Bohnert A, et al. CDC guideline for opioid prescribing associated with reduced dispensing to certain patients with chronic pain. Health Aff. 2021;40(11):1766–1775.
- National Institute on Drug Abuse. Overdose death rates. Trends & Statistics; 2022 [cited 2022 Jul 31]. Available from: https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates
- O'Donnell JK, Gladden RM, Seth P. Trends in deaths involving heroin and synthetic opioids excluding methadone, and law enforcement drug product reports, by census region – United States, 2006–2015. MMWR Morb Mortal Wkly Rep. 2017;66(34):897–903.
- Seth P, Scholl L, Rudd RA, et al. Overdose deaths involving opioids, cocaine, and psychostimulants – United States, 2015–2016. MMWR Morb Mortal Wkly Rep. 2018;67(12):349–358.
- Liu S, O'Donnell J, Gladden RM, et al. Trends in nonfatal and fatal overdoses involving benzodiazepines – 38 states and the District Of Columbia, 2019-2020. MMWR Morb Mortal Wkly Rep. 2021;70(34):1136–1141.
- Eeckhaut MCW, Wagner J, Neitzke-Spruill L, et al. Is the gender gap in overdose deaths (still) decreasing? An examination of opioid deaths in Delaware, 2013–2017. J Stud Alcohol Drugs. 2020;81(1):68–73.
- Wu A, Phan C, Nguyen KC, et al. Trends in hydrocodone combination product exposures reported to California poison control system (CPCS) following DEA rescheduling. Clin Toxicol. 2021;59(4):313–319.
- Driller G, Plasencia E, Apollonio DE. Retrospective review of nicotine exposures in California from 2012 to 2018 and analysis of the impacts of e-cigarette regulations. BMJ Open. 2021 2;11(3):e043133.
- Castillo-Carniglia A, González-Santa Cruz A, Cerdá M, et al. Changes in opioid prescribing after implementation of mandatory registration and proactive reports within California’s prescription drug monitoring program. Drug Alcohol Depend. 2021;218:108405.